CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO
Medicines to prolong the life of lung cancer patients, as well as treatments for osteoporosis and drug-resistant infections, have been approved under a new €20m deal by the HSE.